Johnson & Johnson (NYSE:JNJ) Given New $280.00 Price Target at HSBC

Johnson & Johnson (NYSE:JNJ) had its target price raised by research analysts at HSBC from $265.00 to $280.00 in a research note issued on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HSBC’s price objective points to a potential upside of 16.26% from the company’s current price.

Several other equities research analysts have also recently commented on the stock. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research report on Wednesday, January 28th. BMO Capital Markets reiterated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, December 11th. Freedom Capital lowered shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 16th. Scotiabank restated an “outperform” rating on shares of Johnson & Johnson in a report on Thursday, January 22nd. Finally, Guggenheim upped their price target on Johnson & Johnson from $227.00 to $240.00 and gave the company a “buy” rating in a report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $236.57.

Johnson & Johnson Price Performance

JNJ traded down $2.35 during trading on Tuesday, reaching $240.84. The stock had a trading volume of 1,430,292 shares, compared to its average volume of 8,924,616. The stock has a 50 day moving average of $232.69 and a two-hundred day moving average of $207.13. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $580.09 billion, a price-to-earnings ratio of 21.78, a price-to-earnings-growth ratio of 2.38 and a beta of 0.34. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $251.71.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, equities analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Insider Activity

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the company’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 30,142 shares of company stock worth $7,360,528. Company insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Johnson & Johnson

Several institutional investors and hedge funds have recently modified their holdings of the stock. Blueline Advisors LLC acquired a new position in Johnson & Johnson in the 4th quarter worth about $25,000. Cresta Advisors Ltd. bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $26,000. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson in the third quarter worth approximately $26,000. DecisionPoint Financial LLC raised its position in Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock valued at $30,000 after acquiring an additional 75 shares in the last quarter. Finally, Bay Harbor Wealth Management LLC lifted its stake in Johnson & Johnson by 49.0% in the fourth quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after acquiring an additional 49 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst raises price target to $280, arguing JNJ’s pipeline, recurring revenues and margin resilience justify more upside — this bullish call supports investor confidence in the stock’s further appreciation. Why One Analyst Thinks Johnson & Johnson Reaches $280
• Positive Sentiment: JNJ submitted a Type II variation to the European Medicines Agency seeking approval for TECVAYLI (teclistamab) in relapsed/refractory multiple myeloma — EU approval would materially expand oncology revenue potential. Johnson & Johnson (JNJ) Targets Opportunities around Multiple Myeloma with TECVAYLI
• Positive Sentiment: Early‑stage data for Erda‑iDRS in non‑muscle‑invasive bladder cancer met key endpoints (strong responses, durable control, manageable safety) — clinical progress can de‑risk future oncology catalysts and licensing/launch optionality. JNJ’s Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
• Positive Sentiment: Johnson & Johnson launched a pulsed field ablation (PFA) technology in Peru for atrial fibrillation, marking continued device expansion into emerging markets — incremental procedural/device revenue and share gains in electrophysiology. Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch
• Neutral Sentiment: Market commentary asks whether JNJ’s strong multi‑year run (large YTD/1‑year gains) leaves valuation stretched — this raises the risk of short‑term consolidation even if fundamentals remain intact. Is It Time To Reassess Johnson & Johnson (JNJ) After Strong Multi Year Share Price Gains

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.